Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBriacell Therapeutics Corp

Briacell Therapeutics Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.45 CAD 0.25 ( 5.95%)
Last update at 2026-11-04T19:42:00Z
VOLUME
4282
Market Cap
39.30M

Momentum Score

…

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.28
Low
4.62
High
52 Week Price Range
4.95
Low
135.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing cancer immunotherapies targeting solid tumors through cell‑based and immuno‑oncology approaches. Long-term growth could be supported by positive clinical trial outcomes, regulatory progress, strategic collaborations and combinations with checkpoint inhibitors, and investors may find the company attractive for its differentiated platform and potential to address unmet needs in advanced cancers.
The company faces material risks from clinical trial failure, regulatory setbacks, limited revenue and cash runway that may require dilutive financings, and intense competition in immuno‑oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.20
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-179.21%
Net Debt
-10.49M
ROCE
-208.14%
Diluted EPS TTM
-19.77

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Income before tax -36.83M -0.01M -20.30M -11.55M 3.69M
Minority interest - 0.14M - - -
Net income -36.50M -0.01M -20.30M -11.58M 3.69M
Selling general administrative 5.93M 0.01M 7.94M 7.27M 3.67M
Selling and marketing expenses - 0.00M - - -
Gross profit -0.15M -0.11M - - -
Reconciled depreciation - 0.08M 0.02M 0.02M 0.02M
Ebit -36.78M -0.05M - -15.29M 3.69M
Ebitda -36.63M -0.05M - -11.50M 3.71M
Depreciation and amortization 0.15M 0.00M - 3.79M 0.02M
Operating income -37.73M -0.05M -23.27M -15.29M 3.69M
Other operating expenses 37.73M 0.05M - 0.00M 3.69M
Interest expense 0.05M - 0.00M 0.00M 0.05M
Interest income 0.65M 28.40M 0.85M 0.14M 1.75M
Net interest income - 0.29M 0.89M -11.52M -0.04M
Income tax expense - - - 0.03M -0.05M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 37.59M 0.05M 23.27M -0.00M -3.69M
Cost of revenue 0.15M 0.11M - - -
Total other income expense net 0.90M 0.04M 2.08M 3.74M 6.58M
Net income from continuing ops - -4.93M -20.30M -26.84M -0.43M
Net income applicable to common shares -26.31M -4.79M -20.30M -26.84M -13.82M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total assets 21.65M 5.87M 27.16M 42.58M 58.04M
Intangible assets 0.18M 0.20M 0.22M 0.23M 0.25M
Other current assets 1.28M - - 1.28M -
Total liab 4.32M 8.56M 30.94M 32.25M 0.78M
Total stockholder equity 24.72M -2.38M -3.78M 10.33M 57.26M
Other current liab -0.56M - - 0.48M -
Common stock 140.66M - 69.59M 65.59M 54.78M
Capital stock - 72.17M 69.59M 65.59M 54.78M
Retained earnings -154.51M -85.44M -80.65M -60.35M -15.75M
Other liab - - - 31.31M 29.79M
Cash 10.49M 0.86M 21.25M 41.04M 57.27M
Total current liabilities 3.98M 7.46M 1.80M 0.94M 0.56M
Net debt -10.49M - - -41.04M -57.24M
Short term debt - - 0.00M 0.00M 0.00M
Short long term debt total - - - - 0.03M
Other stockholder equity 129.23M - -0.14M 5.23M 18.37M
Total current assets 19.93M 3.65M 26.95M 42.35M 57.80M
Long term investments - 0.42M 0.00M 0.00M 0.00M
Net tangible assets - - - 10.10M 27.43M
Short term investments 7.37M - - - -
Net receivables 0.78M - 0.02M 0.02M 0.01M
Long term debt - - - 0.00M 0.02M
Accounts payable 4.54M 7.17M 1.12M 0.46M 0.21M
Accumulated other comprehensive income 38.57M - - -0.14M -0.14M
Non currrent assets other 0.52M - - - -
Non current assets total 1.72M 2.22M 0.22M 0.23M 0.25M
Long term debt total - - 0.00M 0.00M 0.02M
Breakdown 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Type yearly yearly yearly yearly yearly
Date 2025-07-31 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Investments - -0.68M - - 0.00M
Change to liabilities - - - 0.25M -1.41M
Total cashflows from investing activities -7.65M -0.68M - - 0.00M
Net borrowings - - - - -0.33M
Total cash from financing activities 45.45M 4.42M 3.95M -3.74M 65.00M
Change to operating activities - - - -0.63M -0.89M
Net income -26.56M -4.93M -20.30M -26.84M -0.43M
Change in cash 9.63M -20.39M -19.79M -16.23M 57.25M
Begin period cash flow 0.86M 21.25M 41.04M 57.27M 0.02M
End period cash flow 10.49M 0.86M 21.25M 41.04M 57.27M
Total cash from operating activities -28.17M -24.13M -23.74M -12.48M -7.75M
Issuance of capital stock - 4.42M 4.00M 0.00M 51.62M
Depreciation 0.11M 0.08M 0.02M 0.02M 0.02M
Other cashflows from investing activities -0.33M -0.23M - - 0.00M
Change to account receivables 1.02M -0.73M - -0.01M 0.01M
Sale purchase of stock 45.45M 4.42M 3.95M -10.17M 51.54M
Other cashflows from financing activities -17.94M - 0.00M 6.43M 13.92M
Change to netincome - - - 14.73M 8.33M
Capital expenditures 0.00M 0.46M 0.00M 0.00M 0.00M
Change in working capital -2.66M 7.05M -3.53M -0.39M -2.28M
Stock based compensation 0.78M 1.80M 2.19M 3.07M 1.97M
Other non cash items 0.16M -28.14M - 11.66M -7.02M
Free cash flow -28.17M -24.58M -23.74M -12.48M -7.75M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BCT
Briacell Therapeutics Corp		 0.25
5.95%		 4.45 - - - 0.93 -1.87
EPRX
Eupraxia Pharmaceuticals Inc		 -0.17
1.76%		 9.48 - - - 8.45 -3.88
FRX
Fennec Pharmaceuticals Inc		 0.20
1.35%		 14.99 - 21.01 6.95 6.35 20.27
MSCL
Satellos Bioscience Inc.		 -
-%		 9.00 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.10
9.80%		 0.92 - 3.87 4263.36 9.74 -6.36

Profile*

Briacell Therapeutics Corp

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate theclinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Bellevue Centre, West Vancouver, BC, Canada, V7T 2X1

604 921 1810

https://briacell.com

Name Title Year Born
Dr. William V. Williams M.D. CEO, Pres & Director 1956
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBA CFO & Corp. Sec. 1973
Dr. Miguel A. Lopez-Lago Chief Scientific Officer 1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPH Chief Medical Officer 1962
Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Research Advisor & Member of Scientific Advisory Board 1946
Dr. William V. Williams M.D. CEO, President & Director 1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CFO & Corporate Secretary 1973
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer 1969
Dr. William V. Williams FCPA, M.D. CEO, President & Director 1955
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…